The risk for anemia with targeted therapies for solid tumors

Oncologist

Volumn 17, Issue 5, 2012, Pages 715-724

  Barni, Sandro ^a   Cabiddu, Mary ^a   Guarneri, Paolo ^a   Lonati, Veronica ^a   Petrelli, Fausto ^a  

^a Azienda Ospedaliera   (Italy)

Author keywords

Anemia; Erythropoiesis stimulating agents; Meta analysis; Solid tumors; Targeted therapies

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; VASCULOTROPIN ANTIBODY;

ANEMIA; ARTICLE; ERYTHROCYTE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SOLID TUMOR;

ANEMIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84861624299     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0024     Document Type: Article

References (95)

1. Hurter B, Bush NJ. Cancer-related anemia: Clinical review and management update. Clin J Oncol Nurs 2007;11:349-359.
2. Payne J, Piper B, Rabinowitz I et al. Biomarkers, fatigue, sleep, and depressive symptoms in women with breast cancer: A pilot study. Oncol Nurs Forum 2006;33: 775-783.
3. Cella D, Lai JS, Chang CH et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94:528-538.
4. NCCN Clinical Practice Guidelines in Oncology. Available at http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf, accessed December 16, 2011.
5. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
6. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
7. Phase III trial of Avastin plus chemotherapy showed 30 percent improvement in overall survival in first-line non-squamous, non-small cell lung cancer. Available at http://www.roche.com/inv-update-2005-05-16, accessed April 3, 2012.
8. Socinski MA, Novello S, Brahmer JR et al. Multicenter, phase II trial of sunitinib in previously treated, advance non-small-cell lung cancer. J Clin Oncol 2008; 26:650-656.
9. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350: 2335-2342.
10. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005:23:3502-3508.
11. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
12. Kabbinavar FF, Schulz J, McCleod M. et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705.
13. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Onco 2003:21:60-65.
14. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: Safety profile and management of adverse events. Semin Oncol 2006;33:S26-S34.
15. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005;69(suppl 3):25-33.
16. Gkountouvas A, Kostoglou-Athanassiou I, Veniou E et al. Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer. Thyroid 2010;20: 597-600.
17. Price J, Shaarbaf R, Wood L. Sunitinib causes macrocytosis in patients with advanced renal cell carcinoma. Curr Oncol 2010;17:30-33.
18. Schallier D, Trullemans F, Fontaine C et al. Tyrosine kinase inhibitor-induced macrocytosis. Anticancer Res 2009;29:5225-5228.
19. Billemont B, Izzedine H, Rixe O. Macrocytosis due to treatment with sunitinib. N Engl J Med 2007;357: 1351-1352.
20. Rini BI, Choueiri TK, Elson P et al. Sunitinibinduced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 2008;113:1309-1314.
21. Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660-664.
22. Bevacizumab + sunitinib: Microangiopathic haemolytic anaemia. A serious drug interaction between 2 cancer drugs. Prescrire Int 2009;18:165.
23. Jain R, Mathew P, Wood CG, Tannir NM. Sunitinib-induced acute hemolysis without hypertension: A case report. Clin Genitourin Cancer 2008;6:122-123.
24. Berchem G, Dewilde S, Mahassen P. A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer. Bull Soc Sci Med Grand Duche Luxemb 2009;1:7-9.
25. Kapiteijn E, Brand A, Kroep J et al. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007;18:1745-1747.
26. Siau K, Varughese M. Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: A case report. Med Oncol 2010;27:1057-1059.
27. Frangié C, Lefaucheur C, Medioni J et al. Renal thrombotic microangiopathy caused by anti-VEGF-anti-body treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007;8:177-178.
28. Bollée G, Patey N, Cazajous G et al. Thrombotic microangiopathy secondary to VEGF pathway inhibi tion by sunitinib. Nephrol Dial Transplant 2009;24:682-685.
29. Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann Intern Med 1997;127:531-537.
30. NCI Common Terminology Criteria for Adverse Events. Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf, accessed December 16, 2011.
31. NCI Common Terminology Criteria for Adverse Events. Available at http://ctep.cancer.gov/protocolDevelopment/electronicapplications/docs/ctcaev2to3.pdf, accessed December 16, 2011.
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
33. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127: 820-826.
34. Butts CA, Bodkin D, Middleman EL et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007;25:5777-5784.
35. Burtness B, Goldwasser MA, Flood W et al. Eastern Cooperative Oncology Group. Phase HI randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-8654.
36. Cascinu S, Berardi R, Labianca R et al. Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer. A randomised, multicentre, phase II trial. Lancet Oncol 2008;9:39-44.
37. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006; 368:1329-1338.
38. Escudier B, Eisen T, Stadler WM et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
39. Escudier B, Pluzanska A, Koralewski P et al.; AVOREN Trial investigators. Bevacizumab plus inter-feron alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-2111.
40. Gatzemeier U, Pluzanska A, Szczcsna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007:25:1545-1552.
41. Gatzemeier U, Groth G, Butts C et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004;15:19-27.
42. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784.
43. Goss G, Ferry D, Wierzbicki R et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 2009;27:2253-2260.
44. Guarneri V, Frassoldati A, Ficarra G et al. Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. Breast Cancer Res Treat 2008;110:127-134.
45. Hauschild A, Agarwala SS, Trefzer U et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27: 2823-2830.
46. Herbst RS, Prager D, Hermann R et al.; TRIBUTE Investigator Group. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-smallcell lung cancer. J Clin Oncol 2005;23:5892-5899.
47. Herbst RS, Giaccone O, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
48. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 2008;26:3523-3529.
49. Nudes G, Carducci M, Tomczak P et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356: 2271-2281.
50. Joensuu H, Kellokumpu-Lehtinen PL, Bono Pet al. FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
51. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911-917.
52. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-4274.
53. Mathew P, Thall PF, Bucana CD et al. Plateletderived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 2007;13:5816-5824.
54. Mayer EL, Dhakil S, Patel T et al. SABRE-B: An evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010;21:2370-2376.
55. McDermott DF, Sosman JA, Gonzalez R et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 Study Group. J Clin Oncol 2008;26:2178-2185.
56. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epi dermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-3247.
57. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
58. Mok TS, Wu YL, Yu CJ et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced nonsmall-cell lung cancer. J Clin Oncol 2009;27:5080-5087.
59. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-3590.
60. Motzer RJ, Escudier B, Oudard S et al.; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-456.
61. Pirker R, Pereira JR, Szczesna A et al.; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009;373: 1525-1531.
62. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall-cell lung cancer: AVAil. J Clin Oncol 2009;27: 1227-1234.
63. Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 2010;28:2137-2143.
64. Rosell R, Robinet G, Szczesna A et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008;19:362-369.
65. Santoro A, Comandone A, Rimassa L et al. A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Ann Oncol 2008;19:1888-1893.
66. Scagliotti G, Novello S, von Pawel J et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835-1842.
67. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl I Med 2001;344:783-792.
68. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. I Clin Oncol 2008;26:2311-2319.
69. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-2237.
70. Vermorken JB, Mesia R, Rivera F et al. Platinumbased chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
71. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German breast group 26/breast international croun 03-05 study. J Clin Oncol 2009:27:1999-2006.
72. Bornner M, Koeberle D, Von Moos R et al. Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: A randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 2008;19:1288-1292.
73. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.
74. Wildiers H, Fontaine C, Vuylsteke P et al. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010;123:463-469.
75. Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28:3617-3622.
76. Philip PA, Benedetti J, Corless CL et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. I Clin Oncol 2010;28:3605-3610.
77. Bang YJ, Van Cutsem E, Feyereislova A et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, openlabel, randomized controlled trial. Lancet 2010;376: 687-697.
78. Stathopoulos GP, Batziou C, Trafalis D et al. Treatment of colorectal cancer with and without bevacizumab: A phase III study. Oncology 2010;78:376-381.
79. Gaafar RM, Surmont VF, Scagliotti GV et al. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/IL.CP 01/03). Eur J Cancer2011;47:2331-2340.
80. Viéitez JM, Valladares M, Peláez I et al. A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). Invest New Drugs 2011;29:1038-1044.
81. Stinchcombe TE, Peterman AH, Lee CB et al. A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV nonsmall cell lung cancer. J Thorac Oncol 2011;6:1569-1577.
82. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-2114.
83. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
84. Ohtsu A, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-3976.
85. Verbeke N, Beguin Y, Wildiers H et al. High prevalence of anaemia and limited use of therapy in cancer patients: A Belgian survey (Anaemia Day 2008). Support Care Cancer 2012;20:23-28.
86. Harper P, Littlewood T. Anaemia of cancer: Impact on patient fatigue and long-term outcome. Oncology 2005;69(suppl 2):2-7.
87. Caro JJ, Salas M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001; 91:2214-2221.
88. Weisel KC, Yildirim S, Schweikle E et al. Effect of FLT3 inhibition on normal hematopoietic progenitor cells. Ann N Y Acad Sci 2007;1106:190-196.
89. Kimura Y, Ding B, Imai N et al. c-Kit-mediated functional positioning of stem cells to their niches is essential for maintenance and regeneration of adult hematopoiesis. PLoS One 2011;6:e26918.
90. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A sys tematic review and meta-analysis of clinical trials. Lancet Oncol 2009:10:967-974.
91. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23: 792-799.
92. Sher AF. Effect of bevacizumab on the risk of chemotherapy-associated anemia in cancer patients: A meta-analysis. J Clin Oncol 2010;28:15s.
93. NCCN Clinical Practice Guidelines in Oncology. Available at http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf, accessed December 16, 2011.
94. Rizzo JD, Brouwers M, Hurley P et al. American Society of Clinical Oncology; American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996-5010.
95. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. The Oncologist 2008; 13(suppl 3):33-36.